S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
Investing.com -- Everest Group, a prominent global research and consulting firm, has identified Indegene as a leading player in the adoption of generative AI (GenAI) within the life sciences sector. In their report titled ’AI-deas to Action (WA:ACT): Operationalizing Generative AI in Life Sciences’, the Everest Group recognized the comprehensive GenAI capabilities of Indegene, which encompass scale, range of use cases, strategic collaborations, and value provided to clients.
The report emphasized that Indegene’s comprehensive GenAI strategy and enterprise-grade, ready-for-production solutions are assisting life sciences companies in optimizing operations and achieving substantial productivity enhancements across multiple use cases. These use cases cover the clinical, medical, and commercial aspects of the life sciences value chain.
Tarun Mathur, CTO of Indegene, commented on the recognition, stating, “We believe GenAI is a generational opportunity for life sciences leaders to make the strategic leap and drive transformational business impact. We are helping them maximize GenAI’s potential - solve real business challenges, prioritize use cases that deliver clear business outcomes, and realize benefits in a responsible and compliant way.”
The Everest Group evaluated each service provider’s GenAI capabilities based on four specific parameters: scale, focusing on revenue, client reach and pipeline; the quality and impact of industry-specific use cases across the value chain either in pilot or production stages; the nature of strategic partnerships across the board and the capability boost thereof; and the amount of real, measurable value realized by clients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.